Videos

- Career builder (2)
- Events (4)
- FDA (14)
- Interviews (6)
- Pharmacists (4)
- Technology (6)

Pharma Jobs

- Qualty Control and Quality Assurance Jobs (210)
- Administration Jobs (94)
- Clinical Jobs (116)
- Formulation and Process Development jobs (102)
- H R Jobs (63)
- Manufacturing or Production Jobs (92)
- Packaging Jobs (15)
- Pharma Engineering Jobs (137)
- Pharma IT Jobs (28)
- Pharmaceutical Marketing Jobs (54)
- Pharmaceutical sales jobs (470)
- Project Management Jobs (126)
- Regulatory Affairs Jobs (33)
- Research and Development jobs (405)
- Validation Jobs (30)
- Accounting and Finance Jobs (127)

Principal Process Development Scientist-WYETH-USA-, Mol. Biol Andover, MA

in

We are seeking an energetic and experienced cell and molecular biologist to join the Cell and Molecular Sciences group, within Drug Substance Development (DSD), to support the BioPharma pipeline through the development of cell lines and cell culture processes for clinical and commercial DS production. The primary responsibilities of the individual will be to contribute as a technical, operational and strategic leader within an organization focused on the generation of highly productive cell lines expressing recombinant therapeutic proteins. Additionally, the group is also responsible for developing novel expression technologies and strategies for improving the level of recombinant protein expression, and the efficiency with which highly productive cell lines and culture processes are developed.

Click Here For More Information

Review Articles:

Please see Instruction
For Authors and Copyright Agreement Form

Pharma News:

Please email us your news, announcement or info to news @ pharmainfo.net

Pharma Blogs

Importance of Folic acid in pregnancy to prevent neural tube defects (NTD)

Submitted by sailajabyrisetty on Tue, 04/22/2008 - 23:57.

in

MyBlog

Next to cardiac abnormalities, neural tube defects are the second most common major congenital disorders. Spina bifida, a type of NTD, is the most common cause of congenital ambulatory disability.

Awareness about the importance of preventing NTD through sufficient folic acid intake during the periconception period has grown over the past 15 years.

Fortunately, the number of infants born with a NTD has declined. In 1997, 7.5 per 10,000 births in Canada were affected by a NTD (approximately 260 births/year), compared to 11.6 per 10,000 births in 1989. This decrease may be explained by an increase in folic acid supplementation and an improvement in prenatal diagnosis of NTDs, with possible pregnancy termination. Some studies also indicate that perinatal folic acid supplementation decreases the occurrence of defects of the heart, urinary tract, limbs, and possibly orofacial clefts.